- Conditions
- Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
- Interventions
- Finerenone (Kerendia, BAY94-8862)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- Up to 18 Years
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 22
- States / cities
- Aurora, Colorado • Wilmington, Delaware • Gainesville, Florida + 18 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–31
of 7
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Heart Failure, Acute Heart Failure
- Interventions
- Finerenone, Placebo
- Drug
- Lead sponsor
- Colorado Prevention Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 82
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 72 more
- Conditions
- Type 1 Diabetes, T1D Heart Failure, Cardio-renal Vascular Function and Failure, Diabetic Chronic Kidney Disease
- Interventions
- Finerenone, Sotagliflozin
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Portland, Oregon
- Conditions
- Heart Failure
- Interventions
- Finerenone (BAY94-8862), Placebo
- Drug · Other
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 6,016 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 107
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 98 more
- Conditions
- Chronic Kidney Disease, Type 2 Diabetes Mellitus
- Interventions
- Finerenone (Kerendia, BAY94-8862), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 951 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 13
- States / cities
- Northridge, California • Port Hueneme, California • Waterbury, Connecticut + 9 more
- Conditions
- Hypertension (HTN)
- Interventions
- Combination Product: FDC of spironolactone and ER torsemide, Combination Product: Stabilized doses of loop diuretic and finerenone
- Drug
- Lead sponsor
- Sarfez Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Vienna, Virginia
- Conditions
- Diabetic Kidney Disease
- Interventions
- Finerenone (BAY94-8862), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7,352 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 173
- States / cities
- Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 124 more